{"id":21389,"date":"2025-01-13T20:27:08","date_gmt":"2025-01-13T12:27:08","guid":{"rendered":"https:\/\/flcube.com\/?p=21389"},"modified":"2025-01-13T20:27:10","modified_gmt":"2025-01-13T12:27:10","slug":"ouro-medicines-launches-with-120m-series-a-financing-for-cm336-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21389","title":{"rendered":"Ouro Medicines Launches with $120M Series A Financing for CM336 Development"},"content":{"rendered":"\n

Ouro Medicines, the licensee of China-based Keymed Biosciences Inc.\u2019s (HKG: 2162<\/a>) CM336, has successfully launched with a USD 120 million Series A financing round. The California-headquartered biotech, founded by Monograph Capital in partnership with GSK plc (NYSE: GSK<\/a>), saw the funding co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners. Additional participants included Monograph Capital, GSK, UPMC Enterprises, Boyu\/Zoo Capital, LongRiver Investments, and other unnamed investors. This significant funding round positions Ouro Medicines to advance the development of its core product, CM336\/OM336.<\/p>\n\n\n\n

Core Product and Development<\/strong>
Ouro Med\u2019s core product, CM336\/OM336, is a BCMA\/CD3 targeted bispecific antibody (BsAb) in-house developed by Keymed Bio. The product is currently undergoing a Phase II expansion study in China for the treatment of multiple myeloma. This innovative therapy has the potential to significantly impact the treatment landscape for multiple myeloma, a complex and challenging disease.<\/p>\n\n\n\n

License Agreement and Global Rights<\/strong>
In November of last year, Keymed Bio struck a potential USD 620 million license deal with Platina Medicines Ltd (PML), which is wholly owned by Ouro Med. The agreement granted Ouro Med exclusive development, manufacturing, and commercialization rights to CM336 globally, excluding mainland China, Hong Kong, Macau, and Taiwan. This strategic move ensures that Ouro Medicines has the necessary resources and rights to bring CM336 to patients in need worldwide.<\/p>\n\n\n\n

Future Prospects<\/strong>
The successful Series A financing round and the strategic license agreement with Keymed Bio provide Ouro Medicines with a strong foundation to advance the clinical development of CM336\/OM336. With the support of leading investors and the expertise of its partners, Ouro Medicines is well-positioned to make significant strides in the development of novel therapies for multiple myeloma and potentially other related diseases.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Ouro Medicines, the licensee of China-based Keymed Biosciences Inc.\u2019s (HKG: 2162) CM336, has successfully launched…<\/p>\n","protected":false},"author":1,"featured_media":21391,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,184,974,28,914,3134],"class_list":["post-21389","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-gsk","tag-hkg-2162","tag-multi-specific-antibodies","tag-nyse-gsk","tag-ouro-medicines"],"yoast_head":"\nOuro Medicines Launches with $120M Series A Financing for CM336 Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ouro Medicines, the licensee of China-based Keymed Biosciences Inc.\u2019s (HKG: 2162) CM336, has successfully launched with a USD 120 million Series A financing round. The California-headquartered biotech, founded by Monograph Capital in partnership with GSK plc, saw the funding co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners. Additional participants included Monograph Capital, GSK, UPMC Enterprises, Boyu\/Zoo Capital, LongRiver Investments, and other unnamed investors. This significant funding round positions Ouro Medicines to advance the development of its core product, CM336\/OM336.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21389\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ouro Medicines Launches with $120M Series A Financing for CM336 Development\" \/>\n<meta property=\"og:description\" content=\"Ouro Medicines, the licensee of China-based Keymed Biosciences Inc.\u2019s (HKG: 2162) CM336, has successfully launched with a USD 120 million Series A financing round. The California-headquartered biotech, founded by Monograph Capital in partnership with GSK plc, saw the funding co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners. Additional participants included Monograph Capital, GSK, UPMC Enterprises, Boyu\/Zoo Capital, LongRiver Investments, and other unnamed investors. This significant funding round positions Ouro Medicines to advance the development of its core product, CM336\/OM336.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21389\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-13T12:27:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-13T12:27:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1314.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"607\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21389#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21389\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ouro Medicines Launches with $120M Series A Financing for CM336 Development\",\"datePublished\":\"2025-01-13T12:27:08+00:00\",\"dateModified\":\"2025-01-13T12:27:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21389\"},\"wordCount\":301,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21389#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1314.png\",\"keywords\":[\"Finance\",\"GSK\",\"HKG: 2162\",\"Multi-specific antibodies\",\"NYSE: GSK\",\"Ouro Medicines\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21389#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21389\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21389\",\"name\":\"Ouro Medicines Launches with $120M Series A Financing for CM336 Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21389#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21389#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1314.png\",\"datePublished\":\"2025-01-13T12:27:08+00:00\",\"dateModified\":\"2025-01-13T12:27:10+00:00\",\"description\":\"Ouro Medicines, the licensee of China-based Keymed Biosciences Inc.\u2019s (HKG: 2162) CM336, has successfully launched with a USD 120 million Series A financing round. The California-headquartered biotech, founded by Monograph Capital in partnership with GSK plc, saw the funding co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners. Additional participants included Monograph Capital, GSK, UPMC Enterprises, Boyu\\\/Zoo Capital, LongRiver Investments, and other unnamed investors. This significant funding round positions Ouro Medicines to advance the development of its core product, CM336\\\/OM336.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21389#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21389\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21389#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1314.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1314.png\",\"width\":1080,\"height\":607,\"caption\":\"Ouro Medicines Launches with $120M Series A Financing for CM336 Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21389#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ouro Medicines Launches with $120M Series A Financing for CM336 Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ouro Medicines Launches with $120M Series A Financing for CM336 Development - Insight, China's Pharmaceutical Industry","description":"Ouro Medicines, the licensee of China-based Keymed Biosciences Inc.\u2019s (HKG: 2162) CM336, has successfully launched with a USD 120 million Series A financing round. The California-headquartered biotech, founded by Monograph Capital in partnership with GSK plc, saw the funding co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners. Additional participants included Monograph Capital, GSK, UPMC Enterprises, Boyu\/Zoo Capital, LongRiver Investments, and other unnamed investors. This significant funding round positions Ouro Medicines to advance the development of its core product, CM336\/OM336.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21389","og_locale":"en_US","og_type":"article","og_title":"Ouro Medicines Launches with $120M Series A Financing for CM336 Development","og_description":"Ouro Medicines, the licensee of China-based Keymed Biosciences Inc.\u2019s (HKG: 2162) CM336, has successfully launched with a USD 120 million Series A financing round. The California-headquartered biotech, founded by Monograph Capital in partnership with GSK plc, saw the funding co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners. Additional participants included Monograph Capital, GSK, UPMC Enterprises, Boyu\/Zoo Capital, LongRiver Investments, and other unnamed investors. This significant funding round positions Ouro Medicines to advance the development of its core product, CM336\/OM336.","og_url":"https:\/\/flcube.com\/?p=21389","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-13T12:27:08+00:00","article_modified_time":"2025-01-13T12:27:10+00:00","og_image":[{"width":1080,"height":607,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1314.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21389#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21389"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ouro Medicines Launches with $120M Series A Financing for CM336 Development","datePublished":"2025-01-13T12:27:08+00:00","dateModified":"2025-01-13T12:27:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21389"},"wordCount":301,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21389#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1314.png","keywords":["Finance","GSK","HKG: 2162","Multi-specific antibodies","NYSE: GSK","Ouro Medicines"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21389#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21389","url":"https:\/\/flcube.com\/?p=21389","name":"Ouro Medicines Launches with $120M Series A Financing for CM336 Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21389#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21389#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1314.png","datePublished":"2025-01-13T12:27:08+00:00","dateModified":"2025-01-13T12:27:10+00:00","description":"Ouro Medicines, the licensee of China-based Keymed Biosciences Inc.\u2019s (HKG: 2162) CM336, has successfully launched with a USD 120 million Series A financing round. The California-headquartered biotech, founded by Monograph Capital in partnership with GSK plc, saw the funding co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners. Additional participants included Monograph Capital, GSK, UPMC Enterprises, Boyu\/Zoo Capital, LongRiver Investments, and other unnamed investors. This significant funding round positions Ouro Medicines to advance the development of its core product, CM336\/OM336.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21389#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21389"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21389#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1314.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1314.png","width":1080,"height":607,"caption":"Ouro Medicines Launches with $120M Series A Financing for CM336 Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21389#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ouro Medicines Launches with $120M Series A Financing for CM336 Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1314.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21389"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21389\/revisions"}],"predecessor-version":[{"id":21392,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21389\/revisions\/21392"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21391"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}